{"favorite_id": 2202, "calc_type": "calculator", "dosing": false, "full_title_en": "CKD Prediction in HIV+ Patients", "short_title_en": "HIV CKD Prediction", "medium_description_en": "Determines probability of HIV patients developing CKD in the next 5 years, if they take tenofivir or not.", "short_description_en": "5 year likelihood of CKD in HIV.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["HIV/AIDS", "Renal Failure"], "specialty_en": ["Infectious Disease", "Internal Medicine", "Nephrology", "Primary Care"], "chief_complaint_en": ["Agitation", "AMS", "Fever", "Weakness"], "system_en": ["Infectious", "Renal"], "search_abbreviation_en": ["CKD", "ESRD", "ESRF", "HIV", "HCV", "predict"], "slug": "ckd-prediction-hiv-patients", "seo": {"meta_description_en": "The CKD Prediction in HIV+ Patients determines probability of HIV patients developing CKD in the next 5 years, if they take tenofivir or not.", "keywords_en": "ckd, hiv, esrd, hiv kidney disease, hiv kidney prognosis, hiv ckd diagnosis, ckd hiv score, esrd hiv score, ckd prediction hiv, esrd hiv predfition, esrf hiv prediction"}, "content": {"how_to_use": {"use_case_en": "<ul> <li>Patients who are expected to be low-risk for the development of CKD, to confirm this</li> <li>Patients who are expected to be high-risk for the development of CKD, to make sure alternatives to tenofovir are used</li> </ul>", "pearls_pitfalls_en": "<ul> <li>It is well-known that tenofovir is associated with a higher risk of developing chronic kidney disease (CKD).</li> <li>This risk is substantially higher in patients with traditional CKD risk factors.</li> <li>This risk calculator helps determine risk of developing CKD, and may help practitioners choose patients who would be good or poor candidates for tenofovir depending on their overall CKD risks.</li> <li>This score was developed in a US VA patient population, and only males were included in this study.</li> <li>This population was also overall \u201chealthier\u201d than the general VA population in other cardiovascular and renal disease states, with relatively low rates of hyperglycemia or hypertension.</li> </ul>", "why_use_en": "<p>Low risk patients may be good candidates for tenofovir, and high risk patients should avoid tenofovir when determining appropriate anti-retroviral therapies.</p>"}, "next_steps": {"advice_en": "", "management_en": "", "critical_actions_en": "<ul>\n<li>Patients with low scores (0 points) may be good candidates for tenofovir.</li>\n<li>Patients with high scores (&ge;9 points) should avoid tenofovir in their treatment regimen, given their significantly higher risk of developing CKD within 5 years.</li>\n</ul>"}, "about": {"formula_en": "<p>Addition of selected points.</p>", "more_info_en": "<div class=\"table-responsive\">\n<table class=\"table table-bordered table-hover\">\n<tbody>\n<tr>\n<th style=\"text-align: left;\">\n<p>Category</p>\n</th>\n<th style=\"text-align: left;\">Score*</th>\n<th style=\"text-align: left;\">5-year event rate (95% CI)</th>\n</tr>\n<tr>\n<td rowspan=\"10\"><abbr title=\"Tenofivir\">TDF</abbr> users</td>\n<td>\n<p>0</p>\n</td>\n<td>1.4 (0.9, 2.2)</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>2.2 (1.4, 3.3)</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>3.6 (2.9, 4.4)</td>\n</tr>\n<tr>\n<td>\n<p>3</p>\n</td>\n<td>5.3 (4.4, 6.5)</td>\n</tr>\n<tr>\n<td>\n<p>4</p>\n</td>\n<td>7.6 (6.6, 8.8)</td>\n</tr>\n<tr>\n<td>\n<p>5</p>\n</td>\n<td>8.6 (7.4, 10.1)</td>\n</tr>\n<tr>\n<td>\n<p>6</p>\n</td>\n<td>10.9 (9.4, 12.6)</td>\n</tr>\n<tr>\n<td>\n<p>7</p>\n</td>\n<td>13.1 (11.1, 15.4)</td>\n</tr>\n<tr>\n<td>\n<p>8</p>\n</td>\n<td>19.4 (16.3, 23.2)</td>\n</tr>\n<tr>\n<td>\n<p>&ge;9</p>\n</td>\n<td>21.4 (18.1, 25.2)</td>\n</tr>\n<tr>\n<td rowspan=\"10\"><abbr title=\"Tenofivir\">TDF</abbr> non-users</td>\n<td>\n<p>0</p>\n</td>\n<td>0.5 (0.3, 0.9)</td>\n</tr>\n<tr>\n<td>\n<p>1</p>\n</td>\n<td>0.3 (0.1, 0.8)</td>\n</tr>\n<tr>\n<td>\n<p>2</p>\n</td>\n<td>1.5 (1.2, 2.0)</td>\n</tr>\n<tr>\n<td>\n<p>3</p>\n</td>\n<td>1.9 (1.4, 2.4)</td>\n</tr>\n<tr>\n<td>\n<p>4</p>\n</td>\n<td>2.7 (2.2, 3.3)</td>\n</tr>\n<tr>\n<td>\n<p>5</p>\n</td>\n<td>4.1 (3.4, 4.9)</td>\n</tr>\n<tr>\n<td>\n<p>6</p>\n</td>\n<td>5.1 (4.3, 6.1)</td>\n</tr>\n<tr>\n<td>\n<p>7</p>\n</td>\n<td>8.7 (7.4, 10.2)</td>\n</tr>\n<tr>\n<td>\n<p>8</p>\n</td>\n<td>11.0 (9.2, 13.2)</td>\n</tr>\n<tr>\n<td>\n<p>&ge;9</p>\n</td>\n<td>16.4 (14.1, 19.2)</td>\n</tr>\n</tbody>\n</table>\n<p>*Scores of 0 are considered low, while scores &ge;9 are considered high.</p>\n</div>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://journals.lww.com/aidsonline/Abstract/2014/06010/A_chronic_kidney_disease_risk_score_to_determine.6.aspx", "text": "Scherzer R, et. al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS 2014; 28:9, 1289\u20131295."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/25963593", "text": "Scherzer R, Shlipak MG. Risk factors: Individual assessment of CKD risk in HIV-positive patients. Nat Rev Nephrol. 2015 Jul;11(7):392-3. doi: 10.1038/nrneph.2015.75. Epub 2015 May 12."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Rebecca Scherzer", "creator_info": {"about_en": "<p>Rebecca Scherzer, PhD, is an academic administrator at UCSF School of Medicine. She is a research statistician for the Fat Redistribution and Metabolic Change in HIV Infection study and for UCSF's Kidney Health Research Collaborative. Dr. Scherzer research and publications span topics including body composition, metabolic changes, kidney disease and HIV infection-related cardiovascular risk.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-rebecca-scherzer.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Scherzer+R%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Age", "name": "age", "options": [{"label": "19-39 years", "value": 0}, {"label": "40-49 years", "value": 2}, {"label": "50-59 years", "value": 4}, {"label": "60-90 years", "value": 6}], "conditionality": "", "show_points": true, "optional": false}, {"type": "toggle", "label_en": "Glucose >140 mg/dL (7.77 mmol/L)", "name": "gluc", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Systolic BP >140 mmHg", "name": "sbp", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Hypertension", "name": "htn", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Triglycerides >200 mg/dL (>2.26 mmol/L)", "name": "tg", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Proteinuria", "name": "proturia", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "CD4\u207a <200 cells/\u00b5L", "name": "cd4", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "subheading", "subheading": "Past or present tenofivir use can change the predicted outcome of the patient", "subheading_instructions": ""}, {"type": "toggle", "label_en": "Tenofivir (TDF) use", "name": "tenofivir", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "", "show_points": false, "default": 0, "optional": true}], "md5": "29da83eb0dc852204256601deedee08b", "related_calcs": [{"calcId": 2200, "short_title_en": "FIB-4 Index", "slug": "fibrosis-4-fib-4-index-liver-fibrosis"}, {"calcId": 2201, "short_title_en": "VACS 1.0 Index", "slug": "veterans-aging-cohort-study-vacs-10-index"}, {"calcId": 10402, "short_title_en": "VACS 2.0 Index", "slug": "veterans-aging-cohort-study-vacs-20-index"}]}